ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company whose goal is to create and associate treatments with the immune formula for immuno-oncology and autoimmune diseases. The corporate has several clinical and technological platforms adding neoepitopes and monoclonal antibodies agonists or antagonists, all located preferably to fight cancer and autoimmune diseases. Its world-class clinical and preclinical portfolio has a diversified threat profile:
Click and us on Twitter and LinkedInhttps: //twitter.com/OSEIMMUNOhttps: //www.linkedin.com/company/10929673
Contacts
Forward-Looking Statements This press release includes explicit or implied data and statements that may be merely forward-looking data and statements relating to OSE Immunotherapeutics. They’re not ancient facts. These data and statements come with monetary projections based on safe assumptions and evidence made through OSE Immunotherapeutics’ control based on their delight and belief in old trends, existing economic and sectoral conditions, long-term expected progress and other points they consider appropriate.
These forward-looking statements come with statements that sometimes use conditional verbs and involve verbs such as “expect,” “anticipate,” “believe,” “point,” “plan,” or “estimate,” their declinations and conjugations, and similar words. Although your control of Immunotherapeutics believes that forward-looking statements and data are reasonable, OSE Immunotherapeutics shareholders and other investors are cautioned that the realization of such expectations is inherently subject to various dangers, known or unknown, and misleading uncertainties. are already waiting and sometimes outside OSE Immunotherapeutics. These hazards may simply cause real effects and advances that differ materially from those expressed, implied or projected through forward-looking statements. These dangers come with those discussed or known in public archives presented through OSE Immunotherapeutics with the MFA. These forward-looking statements do not guarantee long-term performance. This press release includes only abstract data and should be read from the OSE Immunotherapeutics Universal Reference Document submitted to the MFA on 15 April 2020, adding the annual monetary report for fiscal year 2019, available on the OSE Immunothereutics website. Unless required by applicable law, OSE Immunotherapeutics issues problems with this press release as of the present date and assumes no legal responsibility for updating or reviewing any forward-looking data or statements.